Enalapril ointment vs placebo
Pain · people with postburn pruritus
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
4,703 questions · 15,007 findings · 1,416 reviews
No studies found 2,881 · 19.2%GRADE not reported 1,551 · 10.3%Very low 3,111 · 20.7%Low 3,881 · 25.9%Moderate 2,669 · 17.8%High 914 · 6.1%
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Pulsed high‐intensity laser vs Placebo (sham) laser therapy
Change in burn‐related pruritus (VAS) ( · people with postburn pruritus
Pulsed high‐intensity laser showed no clear difference in change in burn‐related pruritus Itch Severity Scale (ISS) ( compared with placebo laser (moderate certainty).
1 finding from 1 review
- no estimate extracted1 study · 49 participantsModerate
Pulsed high‐intensity laser vs Placebo (sham) laser therapy
Adverse events · people with postburn pruritus
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Pulsed high‐intensity laser vs Placebo (sham) laser therapy
Pain VAS ( · people with postburn pruritus
Pulsed high‐intensity laser showed no clear difference in pain VAS ( compared with placebo laser (moderate certainty).
1 finding from 1 review
- no estimate extracted1 study · 49 participantsModerate
Immunomodulatory drug maintenance therapy vs placebo/observation
Grades 3 and 4 adverse events · people with chronic lymphocytic leukaemia
Immunomodulatory drug maintenance therapy may leads to higher grade 3/4 adverse events compared with placebo/observation (low certainty).
1 finding from 1 review
- Rate ratio 1.82 [1.38, 2.38]2 studies · 400 participantsLow
Immunomodulatory drug maintenance therapy vs placebo/observation
Progression‐free survival · people with chronic lymphocytic leukaemia
Immunomodulatory drug maintenance therapy probably leads to lower progression‐free survival compared with placebo/observation (moderate certainty).
1 finding from 1 review
- HR 0.37 [0.19, 0.73]3 studies · 461 participantsModerate
Immunomodulatory drug maintenance therapy vs placebo/observation
Treatment‐related mortality · people with chronic lymphocytic leukaemia
Immunomodulatory drug maintenance therapy showed no clear difference in treatment‐related mortality compared with placebo/observation (low certainty).
1 finding from 1 review
- Risk ratio 1.22 [0.35, 4.29]3 studies · 458 participantsLow
Immunomodulatory drug maintenance therapy vs placebo/observation
Treatment discontinuation · people with chronic lymphocytic leukaemia
It is very uncertain whether immunomodulatory drug maintenance therapy changes treatment discontinuation compared with placebo/observation (very low certainty).
1 finding from 1 review
- Risk ratio 0.71 [0.47, 1.05]2 studies · 400 participantsVery low
Immunomodulatory drug maintenance therapy vs placebo/observation
All adverse events · people with chronic lymphocytic leukaemia
Immunomodulatory drug maintenance therapy probably leads to higher all adverse events compared with placebo/observation (moderate certainty).
1 finding from 1 review
- Rate ratio 1.41 [1.28, 1.54]3 studies · 458 participantsModerate
Immunomodulatory drug maintenance therapy vs placebo/observation
Overall survival · people with chronic lymphocytic leukaemia
Immunomodulatory drug maintenance therapy showed no clear difference in overall survival compared with placebo/observation (moderate certainty).
1 finding from 1 review
- HR 0.91 [0.61, 1.35]3 studies · 461 participantsModerate
Immunomodulatory drug maintenance therapy vs placebo/observation
Health‐related quality of life ‐ not reported · people with chronic lymphocytic leukaemia
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Vitamin C 1400 mg plus vitamin E 800 mg vs placebo
Frequency of pain crises in the · adults with sickle cell disease (adults with homozygous SCA or sickle beta 0 thalassaemia SCD)
It is very uncertain whether vitamin C 1400 mg plus vitamin E 800 mg changes frequency of pain crisis compared with placebo (very low certainty).
1 finding from 1 review
- RR 1.18 [0.64, 2.18]1 study · 83 participantsVery low
Zinc vs placebo
QoL of participants living with SCD and their caregivers · people with sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Zinc vs placebo
Adverse effects · people with sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Zinc vs placebo
Frequency of hospitalization · people with sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Zinc vs placebo
Frequency of sickle cell‐related complications: number of participants with completely healed leg ulcer ( · people with sickle cell disease
It is very uncertain whether zinc changes frequency of sickle cell‐related complications: number of… compared with placebo (very low certainty).
1 finding from 1 review
- RR 2 [0.6, 6.72]1 study · 34 participantsVery low
Zinc vs placebo
Haemoglobin status · people with sickle cell disease
Zinc may leads to higher haemoglobin status (g/dL) compared with placebo (low certainty).
1 finding from 1 review
- MD 1.26 [0.44, 1.26]1 study · 36 participantsLow
N‐acetylcysteine (1200 mg) vs placebo
Frequency of crisis (number of pain days) · sickle cell disease
N‐acetylcysteine (1200 mg) showed no clear difference in frequency of crisis (number of pain days) compared with placebo (low certainty).
1 finding from 1 review
- Rate ratio 0.99 [0.53, 1.84]1 study · 96 participantsLow
N‐acetylcysteine (1200 mg) vs placebo
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · sickle cell disease
N‐acetylcysteine (1200 mg) showed no clear difference in severity of pain (maximum pain intensity on pain days) compared with placebo (low certainty).
1 finding from 1 review
- MD 0.171 study · 96 participantsLow
N‐acetylcysteine (1200 mg) vs placebo
QoL of participants living with SCD and their caregivers · sickle cell disease
It is very uncertain whether N‐acetylcysteine (1200 mg) changes qoL of participants living with SCD and their caregivers (measured… compared with placebo (very low certainty).
1 finding from 1 review
- no estimate extracted1 study · 96 participantsVery low